1. Aflatoxin B1exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers
- Author
-
Jessica Liu, Chin Lan Jen, San Lin You, Hwai I. Yang, Mei Hsuan Lee, Regina M. Santella, Sheng Nan Lu, Yu Ju Chu, Li Yu Wang, Hui-Chen Wu, and Chien-Jen Chen
- Subjects
0301 basic medicine ,Hepatitis B virus ,Cancer Research ,medicine.medical_specialty ,Cirrhosis ,business.industry ,Case-control study ,Hepatitis B ,medicine.disease ,medicine.disease_cause ,Gastroenterology ,digestive system diseases ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Blood serum ,Oncology ,030220 oncology & carcinogenesis ,Internal medicine ,Hepatocellular carcinoma ,medicine ,Liver cancer ,Viral hepatitis ,business - Abstract
The relation between aflatoxin B1 (AFB1 ) and cirrhosis in chronic carriers of hepatitis B virus (HBV) remains inconclusive. This case-control study nested in a large community-based cohort aimed to assess the effect of AFB1 exposure on cirrhosis and HCC in chronic HBV carriers. Serum AFB1 -albumin adduct levels at study entry were measured in 232 cirrhosis cases, 262 HCC cases and 577 controls. Multivariate-adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs) were estimated using logistic regression. Among all chronic HBV carriers, the time intervals between study entry and diagnosis of HCC, cirrhosis, cirrhotic HCC, and non-cirrhotic HCC were all significantly (p
- Published
- 2017